Congenital cytomegalovirus infection: ICCRG guidelines and management aspects that are at the stage of clinical trials

O.L. Logvinova, E.P. Pomazunovskaya, O.S. Sokur

Abstract


Congenital cytomegalovirus (CMV) infection remains the least recognizable cause of sensoneural hearing loss and anomalies of the nervous system in newborns of developed countries. The lack of unified recommendations negatively affects the global effort to reduce the incidence of congenital anomalies associated with CMV. The own follow-up observations of children with nervous system malformations and sensoneural disorders, as well as the assessment of immunological response to CMV in women during pregnancy and neonatal period determined the in-depth analysis of contemporary world literature. The article presents directions for minimizing the risk of congenital CMV, which are realized in clinical recommendations based on the conclusions of leading world experts on the identification and management of congenital cytomegalovirus infection in pregnant and newborns, and also outlines management perspectives that are at the stage of clinical trials.

Keywords


congenital cytomegalovirus infection; cytomegalovirus; children; pregnant women; newborns

References


Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013 Jan;26(1):86-102. doi: 10.1128/CMR.00062-12.

Hamilton ST, van Zuylen W, Shand A, et al. Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: a systematic review. Rev Med Virol. 2014 Nov;24(6):420-33. doi: 10.1002/rmv.1814.

Tey SK, Goodrum F, Khanna R. CD8+ T-cell recognition of human cytomegalovirus latency-associated determinant pUL138. J Gen Virol. 2010 Aug;91(Pt 8):2040-8. doi: 10.1099/vir.0.020982-0.

Doutre S. Reducing congenital cytomegalovirus infection through policy and legislation in the United States. Microbiology Australia. 2015;36(4):162-164. doi: 10.1071/MA15058.

Walker SP, Palma-Dias R, Wood EM, Shekleton P, Giles ML. Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy Childbirth. 2013 Apr 18;13:96. doi: 10.1186/1471-2393-13-96.

Revello MG, Tibaldi C, Masuelli G. Prevention of primary cytomegalovirus infection in pregnancy. EBioMedicine. 2015 Aug 6;2(9):1205-10. doi: 10.1016/j.ebiom.2015.08.003.

Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis. 2011 Jan 15;52(2):e11-3. doi: 10.1093/cid/ciq085.

Munro SC, Hall B, Whybin LR, et al. Diagnosis of and screening for cytomegalovirus infection in pregnant women. J Clin Microbiol. 2005 Sep;43(9):4713-8. doi: 10.1128/JCM.43.9.4713-4718.2005.

Prince HE, Lapé-Nixon M. Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy. Clin Vaccine Immunol. 2014 Oct;21(10):1377-84. doi: 10.1128/CVI.00487-14.

Leruez-Ville M, Stirnemann J, Sellier Y, et al. Feasibility of predicting the outcome of fetal infection with cytomegalovirus at the time of prenatal diagnosis. Am J Obstet Gynecol. 2016 Sep;215(3):342.e1-9. doi: 10.1016/j.ajog.2016.03.052.

Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis. 2004 Jul 15;39(2):233-9. doi: 10.1086/421999.

Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009 Mar 19;360(12):1191-9. doi: 10.1056/NEJMoa0804749.

Bernstein DI, Munoz FM, Callahan ST, et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial. Vaccine. 2016 Jan 12;34(3):313-9. doi: 10.1016/j.vaccine.2015.11.056.

Adler SP. Cytomegalovirus and child day care: risk factors for maternal infection. Pediatr Infect Dis J. 1991 Aug;10(8):590-4.

Grosjean J, Trapes L, Hantz S, et al. Human cytomegalovirus quantification in toddler’s saliva from day care centers and emergency unit: a feasibility study. J Clin Virol. 2014 Nov;61(3):371-7. doi: 10.1016/j.jcv.2014.07.020.

Boppana SB, Ross SA, Shimamura M, et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med. 2011 Jun 2;364(22):2111-8. doi: 10.1056/NEJMoa1006561.

Revello MG, Tibaldi C, Masuelli G. Prevention of primary cytomegalovirus infection in pregnancy. EBioMedicine. 2015 Aug 6;2(9):1205-10. doi: 10.1016/j.ebiom.2015.08.003.

Buxmann H, Stackelberg OM, Schlößer RL, et al. Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis. J Perinat Med. 2012 Mar 27;40(4):439-46. doi: 10.1515/jpm-2011-0257.

Nigro G, Adler SP, La Torre R, Best AM; Congenital Cytomegalovirus Collaborating Group. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005 Sep 29;353(13):1350-62. doi: 10.1056/NEJMoa043337.

Visentin S, Manara R, Milanese L, et al. Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis. 2012 Aug;55(4):497-503. doi: 10.1093/cid/cis423.

Nigro G, Capretti I, Manganello AM, Best AM, Adler SP. Primary maternal cytomegalovirus infections during pregnancy: association of CMV hyperimmune globulin with gestational age at birth and birth weight. J Matern Fetal Neonatal Med. 2015 Jan;28(2):168-71. doi: 10.3109/14767058.2014.907265.

Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999 May 13;340(19):1462-70. doi: 10.1056/NEJM199905133401903.

Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. 2010 Aug 25;304(8):859-66. doi: 10.1001/jama.2010.1206.

Leruez-Ville M, Ghout I, Bussières L, et al. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am J Obstet Gynecol. 2016 Oct;215(4):462.e1-462.e10. doi: 10.1016/j.ajog.2016.04.003.

Williams EJ, Gray J, Luck S, et al. First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by congenital CMV infection. Arch Dis Child Fetal Neonatal Ed. 2015 Nov;100(6):F501-6. doi: 10.1136/archdischild-2014-306756.

Nishida K, Morioka I, Nakamachi Y, et al. Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of newborn urine screening and antiviral treatment. Brain Dev. 2016 Feb;38(2):209-16. doi: 10.1016/j.braindev.2015.08.003.

Bergevin A, Zick CD, McVicar SB, Park AH. Cost-benefit analysis of targeted hearing directed early testing for congenital cytomegalovirus infection. Int J Pediatr Otorhinolaryngol. 2015 Dec;79(12):2090-3. doi: 10.1016/j.ijporl.2015.09.019.

Gantt S, Dionne F, Kozak FK. Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection. JAMA Pediatr. 2016 Dec 1;170(12):1173-1180. doi: 10.1001/jamapediatrics.2016.2016.

Goderis J, De Leenheer E, Smets K, Van Hoecke H, Keymeulen A, Dhooge I. Hearing loss and congenital CMV infection: a systematic review. Pediatrics. 2014 Nov;134(5):972-82. doi: 10.1542/peds.2014-1173.

Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017 Jun;17(6):e177-e188. doi: 10.1016/S1473-3099(17)30143-3.

Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1997 May;175(5):1080-6.

Kimberlin DW, Lin CY, Sánchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003 Jul;143(1):16-25.

Oliver SE, Cloud GA, Sánchez PJ, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol. 2009 Dec;46 Suppl 4:S22-6. doi: 10.1016/j.jcv.2009.08.012.

Kimberlin DW, Jester PM, Sánchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015 Mar 5;372(10):933-43. doi: 10.1056/NEJMoa1404599.

Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010 Jul;20(4):202-13. doi: 10.1002/rmv.655.




DOI: https://doi.org/10.22141/2224-0551.13.2.2018.129553

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru